Of note, insulin therapy was also introduced in the US groups when maternal blood glucose values exceeded safety levels, 6.7 mmol/L (120 mg/dl) fasting or 11.1 mmol/L (200 mg/dl) post-meal, i.e., much above the usually recommended targets in women with gestational diabetes. The gene discussed is INS; the disease is gestational diabetes.